MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)
Sponsor: AstraZeneca
A PHASE2 clinical study on Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 10 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Sep 2024 — Dec 2024 [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Unknown Status PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Queen Mary University of London
- Vall d'Hebron Institute of Oncology
For direct contact, visit the study record on ClinicalTrials.gov .